Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arbutus Biopharma Corporation | ABUS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.74 | 04:01:54 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.74 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.69 - 3.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.74 | USD |
Arbutus Biopharma Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 491.81M | 179.49M | - | 18.14M | -72.85M | -0.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arbutus Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABUS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.78 | 2.81 | 2.635 | 2.72 | 824,256 | -0.04 | -1.44% |
| 1 Month | 2.59 | 3.29 | 2.30 | 2.94 | 2,193,323 | 0.15 | 5.79% |
| 3 Months | 2.40 | 3.29 | 2.265 | 2.83 | 1,446,339 | 0.34 | 14.17% |
| 6 Months | 1.82 | 3.29 | 1.70 | 2.58 | 1,057,516 | 0.92 | 50.55% |
| 1 Year | 2.62 | 3.29 | 1.69 | 2.44 | 841,612 | 0.12 | 4.58% |
| 3 Years | 3.23 | 6.50 | 1.69 | 3.50 | 1,938,247 | -0.49 | -15.17% |
| 5 Years | 2.75 | 9.00 | 0.81 | 3.66 | 2,062,469 | -0.01 | -0.36% |
Arbutus Biopharma Description
| Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
